European Innovation Center - Clinical

Since few years, there is an increasing penetration of Mass Spectrometry techniques in the Clinical field. MALDI-TOF technology has widely invested microbiological laboratories and LC-MS/MS is replacing many immunoassays tests in clinical chemistry thanks to better precision for quantitation, possibilities of multiplexing tests and the less cross-contamination inherent to Immunoassays tests. Shimadzu is a major player in that revolution and we strive to ease that penetration of Mass Spectrometry by developping new solutions to increase patient outcome.


Development of a Forensic Toxicology Database for screening of DOA on a LCMS tandem

Department of Pharmacology and Toxicology, University Hospital of Limoges, France

"Through the European Innovation Center Shimadzu is the first company who proposes us an actual and effective collaboration. This is a win-win and exciting partnership."

HCC cancer detection with probe electrospray ionization mass spectrometry (PESI-MS)

"For a researcher, having a prototype and the first to try something is a desire your whole life. The instrument is brand new. The approach is brand new. It was a very good opportunity."

Prof. Enrico DAVOLI
Mario Negri Institute for Pharmacological Research Milano, Italy

Development of innovative approaches by mass spectrometry for the detection of biomarkers of interest in the context of Parkinson's desease.

Prof. Christophe HIRTZ
IRMB (Institute for Regenerative Medicine and Biotherapy), University Hospital of Montpellier, France

"Be part of the EUIC Shimadzu is a fantastic opportunity to develop clinical proteomics using last generation and high-level mass spectrometer. Within this long-term partnership, we will be able to strengthen our clinical innovations, acquire additional technical expertise and explore new clinical markets for Shimadzu."

Biobank sample quality control with probe electrospray ionization mass spectrometry (PESI-MS)

"For CBmed the European Innovation Center of Shimadzu is an important partner on our way to identify new biomarkers in the field of medicine by providing an insight into the latest technology and extensive knowledge about metabolomics."

Dr. Barbara PRIETL
CBMED Center for Biomarker Research in Medicine Graz, Austria

Fully automated sample preparation procedure with CLAM-2000 to measure drugs of abus by liquid chromatography tandem mass spectrometry

Department of Pharmacology and Toxicology, University Hospital of Limoges, France

"The CLAM-2000 is the first system that allows to have procedures where no human intervention is necessary when the primary tube is loaded on board the system."


Top of This Page